There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Data availability:

Comments

Comment on this article

Cited by 1

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
Authors: Lingfang Xia, Jin Peng, Ge Lou …

See all cited by

Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: a multicenter, open-label, single-arm, phase II trial

Read this article at

Related collections

Nanopublications (single, attributable and machine-readable assertions in scientific literature)

Comments

Comment on this article

Similar content 2,257

Cited by 1